Colleen Kusy
Stock Analyst at Baird
(0.93)
# 3,741
Out of 4,868 analysts
46
Total ratings
30%
Success rate
-16.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $21.57 | +141.08% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.47 | +34.23% | 4 | Jun 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $55 → $47 | $17.76 | +164.64% | 11 | May 8, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $19.48 | +110.47% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $0.77 | +681.66% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $15.08 | +331.03% | 2 | Nov 13, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $0.36 | +742.46% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $8.33 | +104.08% | 4 | Aug 8, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $9.22 | +171.15% | 1 | Mar 12, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $75.53 | +39.02% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $4.44 | +4,629.73% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.04 | +1,566.67% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $1.78 | +12,821.35% | 1 | Nov 2, 2021 |
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $21.57
Upside: +141.08%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.47
Upside: +34.23%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Outperform
Price Target: $55 → $47
Current: $17.76
Upside: +164.64%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $19.48
Upside: +110.47%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $0.77
Upside: +681.66%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $15.08
Upside: +331.03%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.36
Upside: +742.46%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $8.33
Upside: +104.08%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $9.22
Upside: +171.15%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $75.53
Upside: +39.02%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $4.44
Upside: +4,629.73%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.04
Upside: +1,566.67%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $1.78
Upside: +12,821.35%